Latest current cash for CANF: $5.5M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (December 2025), CANF shows a current cash of $5.5M. That compares with $4.8M in the prior-year period — up 14.6% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, CANF's current cash is now $5.5M (was $4.8M) — a 14.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Can-Fite Biopharma is outperforming or lagging.
Tracking CANF's current cash over time shows whether Can-Fite Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $5.5M That compares with $4.8M in the prior-year period — up 14.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this current cash page, Stockcircle has Can-Fite Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $5.5M) with ownership activity and broader fundamentals.
Can-Fite Biopharma's current cash is $5.5M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.